Navigation Links
Ganeden Biotech Announces Grants for Early Investigators to Research Probiotic GanedenBC30
Date:9/30/2009

CLEVELAND, Sept. 30 /PRNewswire/ -- Ganeden Biotech Inc., makers of the patented probiotic strain GanedenBC30® (Bacillus coagulans GBI-30, 6086), today announced two grants for early investigators. Grants focus on researching the effects of GanedenBC30 on human immune cells. Previous studies have demonstrated the ability of GanedenBC30 to modulate numerous human immune cells, both in vitro and in vivo.

To be eligible, investigators must have a full-time faculty appointment at a research institution or medical school. Applicants must have interest in studying the effects of GanedenBC30 on human immune cells, as well as the capacity to conduct such research.

Two grants will be funded at a maximum of $15,000 for each project. Applicants will be expected to submit a budget outlining how the funds will be used. A meeting with Ganeden's Scientific Board will be required prior to the start of the research, as well as following the research to present the results. Travel for these meetings will be subsidized above the grant amount.

Applications will be reviewed by:

  • Ken Alibek, CEO, AFG Bioscience
  • John Endres, chief scientific officer, AIBMR Life Sciences
  • Sean Farmer, chief scientific officer, Ganeden Biotech
  • Glenn Gibson, professor, University of Reading
  • Gary Huffnagle, professor, University of Michigan
  • David Keller, vice president of scientific operations, Ganeden Biotech

Grant applications will be judged on quality of the proposed experimental design, originality of the proposal, evidence of the applicant's ability to conduct the proposed research, and relevance of the proposed research to the health of the general population.

Please contact Dr. David Keller at keller@ganedenbiotech.com for all requests and submission of applications. The deadline for applications is December 31, 2009.

"Ganeden Biotech is happy to announce these grants to early investigators," said Ganeden Biotech CSO and co-founder Sean Farmer. "We believe that research is core to the probiotics industry, and that these grants will enable early investigators to add to the current body of research demonstrating the health benefits of probiotics."

About Ganeden Biotech

Founded in 1996, Ganeden Biotech Inc. is a private company based in Cleveland, Ohio, and is the largest seller of over-the-counter probiotics in the U.S. through its Digestive Advantage and Sustenex brands. It also licenses its patented probiotic bacteria, GanedenBC30, for use in commercial food and beverage applications as well as in medical foods and dietary supplements. GanedenBC30 was found to be Generally Recognized As Safe (GRAS) by an independent expert panel assembled to assess its safety in use as a food ingredient. Digestive Advantage and Sustenex are available at over 40,000 retailers nationwide including Wal-Mart, CVS/pharmacy, Walgreens, Rite-Aid, Stop & Shop, Giant, Publix, Kroger, and Target. For more information, visit www.digestiveadvantage.com, www.sustenex.com, or www.ganedenlabs.com.

SOURCE Ganeden Biotech Inc.


'/>"/>
SOURCE Ganeden Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Melanoma Cancer Clinical Trial
2. Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC
3. Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
4. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
5. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
6. Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
7. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
8. Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse
9. PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies
10. Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
11. Researchers at Axial Biotech Develop a DNA Test for Scoliosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 8, 2016   HighPoint Solutions today ... (NRG),s pharmacovigilance technology services division.  NRG is a ... an Oracle Argus Specialized partner, providing drug safety ... companies. --> --> ... sciences capabilities and provides a global scale and ...
(Date:2/8/2016)... part of a major growth and expansion initiative, Dune Medical ... Chmura as President of Dune Inc., its U.S. division. ... experience in the medical device space will play a large ... --> --> In her new ... and operational functions in the U.S. She is tasked with ...
(Date:2/8/2016)... Feb. 8, 2016 Velano Vascular, a medical ... hospitalized patients and their practitioners, announced today that the ... Velano will use the proceeds from this financing, an ... in January 2015, to support the development and commercialization ... pediatric populations. Philadelphia , ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... ... While a significant number of women and men with eating disorders report a ... that best predicts the development of an eating disorder. , At the ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... excited to share this important news! AHCC and the Home Health and Hospice ... Clinic, CMS' designee for official ICD coding guidance and clarifications, to address concerns ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is ... this country. The AutismOne 2016 Conference, which is being held May 25-29 at the ... hear elsewhere about helpful interventions and causes of chronic illness in children. , Very ...
(Date:2/7/2016)... Dallas, Texas (PRWEB) , ... February 07, 2016 ... ... its new MyDecision™ program. MyDecision™ empowers employers and organizations with the tools and ... , MyDecision™ combines three elements to cut the cost of providing employee healthcare ...
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX LUT: Summer ... grades to their footage. A LUT is a Lookup Table that contains a mathematical ... color indicated by the table. By manipulating each pixel, LUT's can change each color ...
Breaking Medicine News(10 mins):